EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68 Ga-FAPI-LM3 PET

Jianhao Chen, Doudou Luo, Yaqing Dai, Yangfan Zhou, Yizhen Pang, Hua Wu, Long Sun, Guoqiang Su, Qin Lin, Liang Zhao, Haojun Chen iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Jianhao Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospita…. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Mice, Inbred C57BL, Gallium Radioisotopes, Positron-Emission Tomography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Science Fund for Distinguished Young Scholars of Fujian Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early detection of pulmonary fibrosis is a critical yet insufficiently met clinical necessity. This study evaluated the effectiveness of FAPI-LM3, a 68Ga-radiolabeled heterobivalent molecular probe that targets fibroblast activating protein (FAP) and somatostatin receptor 2 (SSTR2), in the early detection of pulmonary fibrosis, leveraging its potential for early disease identification. A bleomycin-induced early pulmonary fibrosis model was established in C57BL/6 mice for 7 days. FAP and SSTR2 expression levels were quantitatively assessed in human idiopathic pulmonary fibrosis lung tissue samples and bleomycin-treated mouse lung tissues by using western blotting, real-time quantitative PCR (RT-qPCR), and immunofluorescence techniques. The diagnostic performance of FAPI-LM3 was investigated by synthesizing monomeric radiotracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3 alongside the heterobivalent probe 68Ga-FAPI-LM3. These imaging radiopharmaceuticals were used in small-animal PET to compare their uptake in fibrotic and normal lung tissues. Results indicated significant upregulation of FAP and SSTR2 at both RNA and protein levels in fibrotic lung tissues compared with that in normal controls. PET imaging demonstrated significantly enhanced uptake of the 68Ga-FAPI-LM3 probe in fibrotic lung tissues, with superior visual effects compared to monomeric tracers. At 60 min postinjection, early stage fibrotic tissues (day 7) demonstrated low-to-medium uptake of monomeric probes, including 68Ga-DOTA-LM3 (0.45 ± 0.04% ID/g) and 68Ga-FAPI-46 (0.78 ± 0.09% ID/g), whereas the uptake of the heterobivalent probe 68Ga-FAPI-LM3 (1.90 ± 0.10% ID/g) was significantly higher in fibrotic lesions than in normal lung tissue. Blockade experiments confirmed the specificity of 68Ga-FAPI-LM3 uptake, which was attributed to synergistic targeting of FAP and SSTR2. This study demonstrates the potential of 68Ga-FAPI-LM3 for early pulmonary fibrosis detection via molecular imaging, offering significant benefits over monomeric tracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3. This strategy offers new possibilities for noninvasive and precise early detection of pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, SomatostatinMice, Inbred C57BLGallium RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsAnimalsMiceHumansPulmonary FibrosisLungMaleBleomycinEndopeptidasesDisease Models, AnimalFemaleIdiopathic Pulmonary FibrosisMembrane ProteinsSerine EndopeptidasesQuinolinesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

FAPI-LM3fibroblast-activating proteinmolecular imagingpulmonary fibrosissomatostatin receptor 2

Substanzen

Receptors, SomatostatinGallium RadioisotopesRadiopharmaceuticalsBleomycinEndopeptidasesMembrane ProteinsSerine EndopeptidasesQuinolinesFibroblast Activation Protein Alpha68Ga-FAPI

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen…
  • Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
  • Department of Colorectal Tumor Surgery, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361003…

ORCID-Profile: Haojun Chen

Förderung

  • Natural Science Foundation of Fujian Province
  • Science Fund for Distinguished Young Scholars of Fujian Province
  • National Natural Science Foundation of China
  • Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare
  • Key Scientific Research Program for Yong Scholars in Fujian

Zitieren

APA

Chen, J., Luo, D., Dai, Y., Zhou, Y., Pang, Y., Wu, H., Sun, L., Su, G., Lin, Q., Zhao, L., & Chen, H. (2024). Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68 Ga-FAPI-LM3 PET. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00405

Vancouver

Chen J, Luo D, Dai Y, Zhou Y, Pang Y, Wu H, et al. Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68 Ga-FAPI-LM3 PET. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00405

BibTeX
@article{Chen2024,
  author = {Chen, Jianhao and Luo, Doudou and Dai, Yaqing and Zhou, Yangfan and Pang, Yizhen and Wu, Hua and Sun, Long and Su, Guoqiang and Lin, Qin and Zhao, Liang and Chen, Haojun},
  title = {Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68 Ga-FAPI-LM3 PET},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00405}
}
Kostenlos starten →